Illumina, Inc. (NASDAQ:ILMN) Stock Has Consensus Target Price of $238.53

04 Nov 2026, 07:45 by Danessa Lincoln · The Markets Daily

Illumina, Inc. (NASDAQ:ILMN – Get Free Report) has received an average recommendation of “Hold” from the nineteen ratings firms that are presently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $244.24.

A number of research firms have weighed in on ILMN. Royal Bank Of Canada boosted their price objective on Illumina from $230.00 to $310.00 and gave the stock an “outperform” rating in a research note on Monday, October 5th. Piper Sandler raised their target price on Illumina from $225.00 to $305.00 and gave the stock an “overweight” rating in a research note on Monday, September 28th. Barclays raised their target price on Illumina from $160.00 to $200.00 and gave the stock an “underweight” rating in a research note on Wednesday, October 7th. Sanford C. Bernstein reiterated a “market perform” rating and set a $215.00 price target on shares of Illumina in a report on Friday, July 31st. Finally, Leerink Partners boosted their price target on shares of Illumina from $220.00 to $300.00 and gave the company an “outperform” rating in a research report on Tuesday, September 29th.

View Our Latest Stock Analysis on ILMN

Insider Transactions at Illumina

In related news, SVP Christensen Wedel sold 1,033 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the completion of the sale, the senior vice president directly owned 14,023 shares in the company, valued at approximately $2,685,684.96. This trade represents a 6.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith Meister sold 119,501 shares of Illumina stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the transaction, the director directly owned 770,350 shares in the company, valued at $168,244,440. This trade represents a 13.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 1,320,108 shares of company stock valued at $288,195,392 in the last three months. 2.90% of the stock is currently owned by insiders.

Institutional Trading of Illumina

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Baker Tilly Wealth Management LLC raised its position in Illumina by 3.3% in the third quarter. Baker Tilly Wealth Management LLC now owns 1,297 shares of the life sciences company’s stock valued at $355,000 after purchasing an additional 42 shares during the period. Ashton Thomas Securities LLC lifted its stake in Illumina by 3.3% during the third quarter. Ashton Thomas Securities LLC now owns 1,348 shares of the life sciences company’s stock worth $369,000 after purchasing an additional 43 shares in the last quarter. Elevation Wealth Partners LLC boosted its position in shares of Illumina by 19.7% during the third quarter. Elevation Wealth Partners LLC now owns 292 shares of the life sciences company’s stock worth $80,000 after buying an additional 48 shares during the period. Evergreen Capital Management LLC boosted its position in shares of Illumina by 0.5% during the third quarter. Evergreen Capital Management LLC now owns 9,474 shares of the life sciences company’s stock worth $2,593,000 after buying an additional 50 shares during the period. Finally, Pinnacle Associates Ltd. boosted its position in shares of Illumina by 2.2% during the third quarter. Pinnacle Associates Ltd. now owns 2,506 shares of the life sciences company’s stock worth $686,000 after buying an additional 54 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Key Illumina News

Here are the key news stories impacting Illumina this week:

Positive Sentiment: Illumina was selected to provide whole-genome sequencing services for Singapore’s SG-INSIGHT study, expected to cover about 450,000 people—roughly one in 10 residents. The project extends the company’s work in Singapore into broader clinical and public-health applications, offering a significant showcase for precision medicine. Article
Neutral Sentiment: The large population covered by the study could create strategic opportunities, but no contract value, revenue timing, or sequencing volume for Illumina was disclosed, so the near-term financial impact is uncertain. Article
Negative Sentiment: Citigroup raised its price target for ILMN but maintained a “sell” rating, indicating it still sees potential downside. Separately, commentary on the Q3 call cited persistent weakness in research and applied markets, despite strength in clinical sequencing and NovaSeq X placements. Article Article

Illumina Stock Up 5.1%

ILMN stock opened at $238.21 on Friday. The company has a market cap of $36.02 billion, a price-to-earnings ratio of 43.16, a PEG ratio of 3.08 and a beta of 1.46. The company has a current ratio of 2.63, a quick ratio of 2.05 and a debt-to-equity ratio of 0.57. Illumina has a 12 month low of $112.65 and a 12 month high of $309.35. The firm has a 50-day moving average of $249.74 and a two-hundred day moving average of $177.05.

Illumina (NASDAQ:ILMN – Get Free Report) last released its earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, topping analysts’ consensus estimates of $1.36 by $0.26. The business had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.15 billion. Illumina had a net margin of 19.72% and a return on equity of 28.38%. The business’s revenue was up 4.2% on a year-over-year basis. During the same period last year, the company posted $1.34 EPS. As a group, analysts forecast that Illumina will post 5.43 earnings per share for the current fiscal year.

Illumina Company Profile

(Get Free Report)

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.